Antibody therapies for multiple myeloma
Publication date: Available online 26 February 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Ben Ponvilawan, Nipith Charoenngam, Thanitsara Rittiphairoj, Patompong Ungprasert
The objective of this article is to review safety and efficacy of various novel agents that specifically target the dysregulated pathways, with particular attention for elderly patients. Agents like B-cell receptor inhibitors (Bruton ’s tyrosine kinase inhibitors (Ibrutinib), phosphatidylinositol 3-kinase (PI3 Kinase) inhibitors (Idelalisib), spleen tyrosine kinase [Syk] inhibitors (entospletinib), Bcl-2 inhibitors (venetoclax), immunomodulators (lenalidomide), and monoclonal antibodies (obinutuzumab, ofatumumab), have shown a ctivity in CLL with a very favorable toxicity profile.
Guideline recommended day 14 (D14) bone marrow examinations during induction therapy for acute myeloid leukemia have uncertain benefit. The current study evaluated the prognostic significance of D14 bone marrow samples for 486 patients undergoing induction therapy for AML and the subsequent outcomes for induction strategies. D14 bone marrows have prognostic significance but no observed clinical benefit for directing induction therapy.
Data on statin use and risk of multiple myeloma is still conflicting. We performed a systematic review that comprised of terms for “statin” and “multiple myeloma” and identified 10 eligible studies for meta-analysis. The risk of multiple myeloma was significantly lower among statin-users than non-users with the pooled odds ratio of 0.80 (95% CI, 0.68 – 0.93; I2 = 72%).
Ibrutinib-associated arthralgias/myalgias are a frequent adverse event which can occur late in the treatment course and are mostly Grade 1 or 2. For patients with Grade 1 or 2 arthralgias/myalgias, dose reductions can frequently mitigate the side effects and allow patients to continue on therapy, while the majority of patients with Grade 3 toxicity ultimately discontinue therapy. Further study is needed to determine their pathogenesis in order to develop best practice management strategies.
Myelofibrosis (MF) is a BCR-ABL1 negative myeloproliferative neoplasm (MPN) that arises from hematopoietic stem/progenitor cells frequently harboring a somatic driver mutation in one of three genes: JAK2, CALR or MPL. Pathologic features of this hematologic malignancy include myeloproliferation, diffuse bone marrow fibrosis, and overactivation of the JAK-STAT pathway resulting in enhanced inflammatory cytokine release. Common clinical manifestations of MF include systemic symptoms, abnormal peripheral blood counts and splenomegaly, however, it has become increasingly appreciated that there is significant clinical heterogen...
Bone Marrow Transplantation, Published online: 26 February 2020; doi:10.1038/s41409-020-0844-2Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma
Publication date: May 2020Source: Biomedicine &Pharmacotherapy, Volume 125Author(s): Hongchun Liu, Chao Xiong, Junwen Liu, Ting Sun, Zhenzhen Ren, Yuqing Li, Jie Geng, Xuebing Li
Authors: da Costa TP, El-Cheikh MC, Carneiro K Abstract Histone Deacetylase- (HDAC-) dependent epigenetic mechanisms have been widely explored in the last decade in different types of malignancies in preclinical studies. This effort led to the discovery and development of a range of new HDAC inhibitors (iHDAC) with different chemical properties and selective abilities. In fact, hematological malignancies were the first ones to have new iHDACs approved for clinical use, such as Vorinostat and Romidepsin for cutaneous T cell lymphoma and panobinostat for multiple myeloma. Besides these promising already approved iHDA...
Publication date: Available online 24 February 2020Source: Journal of Cardiology CasesAuthor(s): Taku Yasui, Wataru Shioyama, Makiko Oboshi, Tatsuya Nishikawa, Risa Kamada, Toru Oka, Masashi Fujita